RemeGen Dirección

Dirección controles de criterios 3/4

El CEO de RemeGen's es Jianmin Fang , nombrado en Oct 2008, tiene una permanencia de 15.5 años. compensación anual total es CN¥26.54M, compuesta por 20.4% salario y 79.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 12% de las acciones de la empresa, por valor de HK$2.91B. La antigüedad media del equipo directivo y de la junta directiva es de 2.3 años y 3.9 años, respectivamente.

Información clave

Jianmin Fang

Chief Executive Officer (CEO)

CN¥14.7m

Compensación total

Porcentaje del salario del CEO	37.0%
Permanencia del CEO	15.6yrs
Participación del CEO	12.0%
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	4yrs

Actualizaciones recientes de la dirección

Recent updates

RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 35% But Its Business Is Yet to Catch Up

Apr 04

Is RemeGen (HKG:9995) Using Debt In A Risky Way?

Mar 24

RemeGen Co., Ltd. (HKG:9995) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Feb 18

Getting In Cheap On RemeGen Co., Ltd. (HKG:9995) Is Unlikely

Dec 29

RemeGen Co., Ltd. (HKG:9995) Shares Could Be 34% Below Their Intrinsic Value Estimate

Oct 16

RemeGen Co., Ltd. (HKG:9995) Analysts Just Cut Their EPS Forecasts Substantially

Apr 08

RemeGen Co., Ltd. (HKG:9995) Just Reported And Analysts Have Been Cutting Their Estimates

Feb 23

We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely

Jan 21

Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 42%?

Nov 30

We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely

Oct 16

A Look At The Intrinsic Value Of RemeGen Co., Ltd. (HKG:9995)

Aug 24

Here's What RemeGen Co., Ltd.'s (HKG:9995) Shareholder Ownership Structure Looks Like

Feb 09

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jianmin Fang en comparación con los beneficios de RemeGen?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-CN¥2b
Dec 31 2023	CN¥15m	CN¥5m	-CN¥2b
Sep 30 2023	n/a	n/a	-CN¥1b
Jun 30 2023	n/a	n/a	-CN¥1b
Mar 31 2023	n/a	n/a	-CN¥1b
Dec 31 2022	CN¥27m	CN¥5m	-CN¥999m
Sep 30 2022	n/a	n/a	CN¥276m
Jun 30 2022	n/a	n/a	CN¥231m
Mar 31 2022	n/a	n/a	CN¥174m
Dec 31 2021	CN¥8m	CN¥4m	CN¥276m

Compensación vs. Mercado: La compensación total de Jianmin($USD3.66M) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD533.27K).

Compensación vs. Ingresos: La compensación de Jianmin ha sido consistente con los resultados de la empresa en el último año.

CEO

Jianmin Fang (61 yo)

15.6yrs

Permanencia

CN¥14,658,000

Compensación

Dr. Jianmin Fang is Co-Founder at RemeGen Co. Ltd. She has been Director, Chief Executive Officer and served as Chief Scientific Officer of RemeGen Co. Ltd. since October 16, 2008 to 2023 and redesignated...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jianmin Fang	Co-Founder	15.6yrs	CN¥14.66m	12% CN¥ 3.3b
Ruyi He	Chief Medical Officer	no data	CN¥24.01m	0.30% CN¥ 82.4m
Jian Lin	Executive Director	no data	CN¥1.13m	sin datos
Shaojing Tong	CFO & Joint Company Secretary	less than a year	sin datos	sin datos
Kaisheng Huang	Chief Operating Officer	no data	sin datos	sin datos
Marie Zhu	Chief Technical Officer	no data	sin datos	sin datos
Zhulun Wang	Chief Scientific Officer	no data	sin datos	sin datos
Daniel Ross	Chief Business Officer	less than a year	sin datos	sin datos
Xiaoming Yang	Chief Manufacturing Officer	no data	sin datos	sin datos
Pak Yu Tam	Joint Company Secretary	4yrs	sin datos	sin datos

2.3yrs

Permanencia media

61yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 9995 se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jianmin Fang	Co-Founder	15.6yrs	CN¥14.66m	12% CN¥ 3.3b
Ruyi He	Chief Medical Officer	4yrs	CN¥24.01m	0.30% CN¥ 82.4m
Jian Lin	Executive Director	15.8yrs	CN¥1.13m	sin datos
Lorne Alan Babiuk	Member of Scientific Advisory Board	no data	CN¥125.00k	sin datos
Gang Pei	Member of Scientific Advisory Board	no data	sin datos	sin datos
Weidong Wang	Co-Founder & Executive Chairman	10.6yrs	CN¥15.15m	0.16% CN¥ 43.8m
Liqiang Wang	Non-Executive Director	4yrs	sin datos	sin datos
Xiaodi Su	Non-Executive Director	4yrs	sin datos	sin datos
Xianjing Hao	Independent Non-Executive Director	4yrs	CN¥300.00k	sin datos
Guangke Ren	Chairman of the Supervisory Committee	4yrs	sin datos	sin datos
Lan Ma	Independent Non-Executive Director	2.9yrs	CN¥300.00k	sin datos
Yunjin Chen	Independent Non-Executive Director	2yrs	CN¥300.00k	sin datos

4.0yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de 9995 se considera experimentada (3.9 años de antigüedad promedio).

RemeGen Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

RemeGen Co., Ltd., Annual General Meeting, Jun 28, 2024

Remegen Co., Ltd. Appoints Tong Shaojing as Joint Company Secretary

Remegen Co., Ltd. Announces Resignation of Li Jia as Chief Financial Officer

RemeGen Co., Ltd. Announces Resignation of Li Jia as Joint Company Secretary

Less than half of directors are independent

RemeGen Co., Ltd., Annual General Meeting, Jun 29, 2022

Recent updates

RemeGen Co., Ltd., Annual General Meeting, Jun 28, 2024

RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 35% But Its Business Is Yet to Catch Up

Full year 2023 earnings released: CN¥2.80 loss per share (vs CN¥1.88 loss in FY 2022)

New minor risk - Profitability

RemeGen Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Is RemeGen (HKG:9995) Using Debt In A Risky Way?

RemeGen Co. Ltd. Presents Oral Presentation on Evaluation of its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer At ESGO 2024

Full year 2023 earnings released: CN¥2.86 loss per share (vs CN¥1.88 loss in FY 2022)

RemeGen Co., Ltd. (HKG:9995) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

RemeGen Co., Ltd. Provides Earnings Guidance for the Period from January 1, 2023 to December 31, 2023

RemeGen Co., Ltd. Provides Earnings Guidance for the Period from January 1, 2023 to December 31, 2023

New minor risk - Share price stability

RemeGen's Rc88 Obtains FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients

Getting In Cheap On RemeGen Co., Ltd. (HKG:9995) Is Unlikely

RemeGen Co., Ltd.'s Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment

RemeGen Co., Ltd. Announces the Full Approval of. Telitacicept for. Systemic Lupus erythematosus by NMPA

RemeGen Co., Ltd. to Present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in A Late-Breaking Abstract Oral Presentation Session At the American College of Rheumatology

Third quarter 2023 earnings released

RemeGen Co., Ltd. (HKG:9995) Shares Could Be 34% Below Their Intrinsic Value Estimate

Remegen Co., Ltd. Appoints Tong Shaojing as Joint Company Secretary

Remegen Co., Ltd. Announces Resignation of Li Jia as Chief Financial Officer

RemeGen Co., Ltd. Announces Resignation of Li Jia as Joint Company Secretary

Second quarter 2023 earnings released: CN¥0.70 loss per share (vs CN¥0.38 loss in 2Q 2022)

RemeGen Co., Ltd. Announces Results of Phase III Study on Telitacicept for Treatment of Rheumatoid Arthritis in China

Is RemeGen (HKG:9995) In A Good Position To Invest In Growth?

New minor risk - Share price stability

RemeGen Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Is There An Opportunity With RemeGen Co., Ltd.'s (HKG:9995) 35% Undervaluation?

Now 20% undervalued after recent price drop

RemeGen Co., Ltd. (HKG:9995) Investors Are Less Pessimistic Than Expected

Remegen Co., Ltd. Receives Ethics Approval for the Phase I Clinical Trial in Australia

Now 21% undervalued after recent price drop

Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 36%?

Full year 2022 earnings released: CN¥1.81 loss per share (vs CN¥0.57 profit in FY 2021)

Now 20% undervalued

RemeGen Co., Ltd. Announces FDA Approves Ind Application for Telitacicept for Treatment of gMG and Grants It Fast Track Designation

National Medical Products Administration Approves IND Application for RemeGen’s Disitamab Vedotin for Injection, Given Intravenously, in Combination with Gemcitabine Hydrochloride for Injection, Given Intravesically, for Treatment of NMIBC

RemeGen Co., Ltd.'s RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA

Less than half of directors are independent

RemeGen Co., Ltd. Announces Telitacicept Propose to Grant Telitacicept Breakthrough Therapy Designation for the Treatment of Generalised Myasthenia Gravis

RemeGen Co., Ltd. Announces Results of Phase Ii Clinical Study of Telitacicept for Treatment of Myasthenia Gravis (MG) in China

Third quarter 2022 earnings released: CN¥0.37 loss per share (vs CN¥0.74 profit in 3Q 2021)

RemeGen Co., Ltd. to Report Nine Months, 2022 Results on Oct 27, 2022

Remegen Co., Ltd. Receives Orphan Drug Designation from FDA for Treatment of Myasthenia Gravis

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

RemeGen Co., Ltd. Announces Preliminary Result of Telitacicept in the Phase III Comfirmatory Study to Treat Systemic Lupus Erythematosus in China

Second quarter 2022 earnings released

RemeGen Co., Ltd. to Report Q2, 2022 Results on Aug 26, 2022

RemeGen Co., Ltd., Annual General Meeting, Jun 29, 2022

RemeGen Co., Ltd. Approves Appointment of Chen Yunjin as Independent Non-Executive Director

RemeGen's (HKG:9995) Earnings Aren't As Good As They Appear

Less than half of directors are independent

RemeGen Co., Ltd. Announces Executive Changes

Investor sentiment deteriorated over the past week

RemeGen Co., Ltd. (HKG:9995) Analysts Just Cut Their EPS Forecasts Substantially

Consensus revenue estimates fall by 14%

Consensus forecasts updated

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

RemeGen Co., Ltd. (HKG:9995) Just Reported And Analysts Have Been Cutting Their Estimates

Forecast breakeven date moved forward to 2022

Consensus estimates of losses per share improve by 49%

Remegen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome

RemeGen Co., Ltd. Completes the Phase II Clinical Study for Telitacicept to Treat Patients with Primary Sjögren's Syndrome (pSS) in China and Obtained the Relevant Data Readout

We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely

RemeGen Co., Ltd. Announces National Medical Products Administration (Nmpa) Grants Conditional Marketing Approval for Disitamab Vedotin for the Treatment of HER2 Expressing Locally Advanced or Metastatic Urothelial Carcinoma

Forecast breakeven date pushed back to 2023

Consensus forecasts updated